CRECON MEDICAL ASSESSMENT

JP

Series

Series

  • Kobayashi M.Value-based Approach [36] Introduction to analysis guideline(12) Modeling⑦Outcome calculation by Markov model We challenge a change method of the long-term medical cost and outcome. Monthly Medical Information Express. 2021; 1:78-80. (in Japanese)

  • Kobayashi M.Value-based Approach [35] Introduction to analysis guideline(11) Modeling⑥Cohort simulation utilizing the Markov model Let’s simulate long-term change of the chronic disease. Monthly Medical Information Express. 2020; 12:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [34] Introduction to analysis guideline(10) Modeling⑤Structure of the Markov model Learn the optimal Markov model for an analysis of the chronic disease. Monthly Medical Information Express. 2020; 11:80-82. (in Japanese)

  • Kobayashi M.Value-based Approach [33] Introduction to analysis guideline(9) Modeling④Value of the information Think about a value of the information in HTA by the decision tree model. Monthly Medical Information Express. 2020; 10:78-80. (in Japanese)

  • Kobayashi M.Value-based Approach [32] Introduction to analysis guideline(9) Modeling③Cost effectiveness analysis by the decision tree model Learn the cost effectiveness analysis of decision tree for an infection. Monthly Medical Information Express. 2020; 9:70-72. (in Japanese)

  • Kobayashi M.Value-based Approach [31] Introduction to analysis guideline(9) Modeling②Decision Tree  Learn the basics of model analysis in decision tree. Monthly Medical Information Express. 2020; 8:78-81. (in Japanese)

  • Kobayashi M.Value-based Approach [Special edition] Simulate the infection situation of new coronavirus. A thorough description of the number of reproduction and sensitive analysis! Monthly Medical Information Express. 2020; 7:36-41. (in Japanese)

  • Kobayashi M.Value-based Approach [30] Introduction to analysis guideline(9) Modeling①The model has the essence of HTA for Japan! The person controlling a model wins HTA for Japan! Monthly Medical Information Express. 2020; 6:78-80. (in Japanese)

  • Kobayashi M.Value-based Approach [29] Introduction to analysis guideline(8) Effect indicator③Problem of the QOL Value evaluation The most important QOL Value evaluation in HTA for Japan. Monthly Medical Information Express. 2020; 5:76-78. (in Japanese)

  • Kobayashi M.Value-based Approach [28] Introduction to analysis guideline(7) Effect indicator②QOL Value Learn the investigation method of QOL value calculation. Monthly Medical Information Express. 2020; 3:78-80. (in Japanese)

TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA